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Quantitative methods were established to determine the level of maturation of human embryonic stem cell-derived ventricular
cardiomyocytes (hESC-vCMs) that were treated with different metabolic stimulants (i.e., isoproterenol and oleic acid) during early
differentiation. Cells were double-immunolabeled with 𝛼-actinin and COX IV antibodies, to label themyofibrils andmitochondria,
respectively, after which images were acquired via confocal microscopy. In order to determine the extent of differentiation,
image analysis protocols were then used to quantify cell shape and area, as well as the degree of myofibrillar organization and
intercalation of mitochondria between the myofibrils within the cells. We demonstrated that oleic acid or isoproterenol alone,
or a combination of the two, induced a more elongated hESC-vCM phenotype than the untreated controls. In addition, cells
treated with isoproterenol alone exhibited a similar level of myofibrillar organization as the controls, but those treated with oleic
acid with/without isoproterenol exhibited a more organized (parallel) orientation of myofibrils. The combined isoproterenol/oleic
acid treatment also resulted in enhanced intercalation of mitochondria between the myofibrils. We suggest that these quantitative
morphometric methods might serve as simple and effective tools that can be utilized in the determination of the level of structural
maturation of hESC-vCMs.
1. Introduction
In a recent study, data collected by the American Heart
Association from 190 countries, confirmed that heart disease
remains one of the main causes of premature death after
stroke and cancer in many parts of the world today [1]. Ter-
minal heart failure is caused by conditions such as ischemic
heart disease, hypertension, and atrial fibrillation and is
characterized by the irreversible loss of significant numbers
of cardiomyocytes [2]. Furthermore, when cardiomyocytes
malfunction due to disease (or aging), the limited regen-
erative nature of terminally differentiated cells in the adult
human heart means that the repair of the myocardium is
severely restricted, and this can be fatal for the patient. Many
of the current treatments of heart disease are palliative in
nature [3] and while heart transplantation is considered to
be the last hope in many cases, it is severely limited by the
lack of suitable donor organs [4]. Much of our current under-
standing of the mechanisms that regulate heart development
in humans has been extrapolated from data acquired from
animal model systems such as the mouse and zebrafish [5–9].
Even though these animal studies have yielded a lot of useful
information regarding heart development, various species-
specific differences have been identified [10]; thus, there is
still much to be discovered specifically about the formation
and regeneration of the human heart.
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It has been less than two decades since embryonic stem
cells (ESCs) were first successfully isolated from the inner cell
mass of blastocyst-stage human embryos [11]. Thomson et al.
[11] demonstrated that these cells have a normal karyotype
and undergo undifferentiated proliferation but still maintain
their pluripotent nature and are thus able to differentiate into
endoderm, mesoderm, and ectoderm cells, depending on the
external cues they receive. At this time, the significance of
having readily available human embryonic stem cells (hESCs)
for transplantation medicine, for drug discovery studies,
and for basic developmental biology research was quickly
appreciated. More recently, a method for reprogramming
already differentiated cells (i.e., embryonic and adult fibrob-
lasts) from mouse into pluripotent stem cells was described
[12], shortly after which, two groups generated induced
pluripotent stem cells (iPSCs) fromhumanfibroblasts [13, 14].
Since then, the ready availability of hESCs and iPSCs as well
as the effective differentiation of both these types of cells into
cardiomyocytes [15–17] has provided scientists and clinicians
with additional tools to study early heart development, as
well as an in vitro model of cardiac disease. Furthermore,
over the last few years, the idea of using cardiomyocytes in
cell-replacement therapy has started to be considered for the
treatment of heart disease [18, 19]. However, a lot of basic
research is still required before this becomes a viable clinical
option [20], largely because human ESCs and iPSCs appear
to be structurally and functionally immature [15, 21–23]. For
example, Kehat et al. [15] described the structural and func-
tional properties of hESC-derived cardiomyocytes (hESC-
CMs) as being reminiscent of early-stage cardiomyocytes,
such that although several cardiac genes and transcription
factors are expressed in these cells, as are various cardiac-
specific proteins, the lack of organization of the myofibrils
is a characteristic of the phenotype of immature cells. Rao
et al. [22] also described the immature phenotype of both
ESC- and iPSC-derived cardiomyocytes and attempted to
induce a more mature phenotype in the latter, by growing
cells on a polydimethylsiloxane (PDMS) scaffold containing
microgrooves coated with fibronectin. They showed that
although iPSC-derived cardiomyocytes did adopt a more
mature phenotype when cultured under these conditions,
the patterns of gene expression remained unchanged [22].
Most recently, Keung et al. [23] also characterized the func-
tional and structural properties of hESC-derived ventricular
cardiomyocytes (hESC-vCMs). They reported that whereas
human adult cardiomyocytes are rod-shaped and in the
order of 100 𝜇m in length, hESC-vCMs are relatively small
in size and frequently round in shape (i.e., just 10–20𝜇m in
diameter). In addition, the rounded shape is maintained even
during long periods in culture, although there is an increase
in cell size over time. Keung et al. [23] also reported that the
organization of contractile proteins in hESC-vCMs is poor
such that myofibrils are at low density and organized in a
randommanner within the cytoplasm of these cells. It is thus
clear from these various reports that it is especially impor-
tant to characterize the morphological and ultrastructural
properties of cells as they mature and in particular quantify
parameters whenever possible, as this will help researchers to
determine the differentiation status of cells and hence their
ability to perform in cell replacement and transplantation
procedures.
Even though themetabolicmechanisms that drive cardiac
development are still largely unknown [24], a number of
groups are starting to investigate the different biological
cues that might be involved in driving maturation, which
would allow strategies to expedite this process in vitro to
be developed. In this study, hESC-vCMs were treated with
isoproterenol, oleic acid, or a combination of both, and the
effect of these pharmacological agents on cell maturation was
compared with that of untreated (control) cells. Isoproterenol
is a 𝛽-adrenoceptor agonist, which induces an influx of
intracellular Ca2+ into cardiomyocytes and, in this way,
stimulates cell contraction [15, 25–27], whereas oleic acid is a
cis-monounsaturated long-chain fatty acid that is reported to
play a cardioprotective role bymodulating the lipid properties
of the plasma membrane and by affecting cell signaling
through its action on ion channel function [28]. Long-chain
fatty acids such as oleic acid have also been shown to be
an important source of energy that are required for cardiac
function [29], as well as playing a role in signal transduction
pathways in heart tissue [30] and promoting the maturation
of energy metabolism in cardiomyocytes via activation of the
peroxisome proliferator-activated receptor-𝛼 (PPAR-𝛼) [31].
In our study, following treatment with isoproterenol
and/or oleic acid, cells were immunolabeled with antibodies
for 𝛼-actinin and COX IV to identify the myofibrils and
mitochondria, respectively [32, 33], and then counterstained
with DAPI to label the nuclei, and images were acquired
via laser scanning confocal microscopy. Methods were then
developed to determine the level of maturation of hESC-
derived ventricular cardiomyocytes via quantification of four
distinct morphological characteristics: cell shape, cell area,
orientation of the myofibrils, and the level of intercalation of
the mitochondria with the myofibrils.
2. Materials and Methods
2.1. Culture and Ventricular Specification of Human
Embryonic Stem Cells. Ventricular cardiomyocytes were
generated from the hES2 human embryonic stem cell (hESC)
line as described previously [34]. In brief, undifferentiated
hES2 cells were cultured alone (i.e., without feeder cells)
in 6-well plates (Corning, Tewksbury, MA, USA), coated
with Matrigel (Discovery Labware, Corning, New York,
USA) and maintained in mTeSR1 medium (Stem Cell
Technologies, Vancouver, BC, Canada). When the cells
reached approximately 80% confluence, differentiation was
initiated when hESC colonies were dissociated into single
cells using Accutase (Invitrogen Life Technologies, Carlsbad,
CA, USA) and then these were cultured in mTeSR1 medium
with Matrigel (40 𝜇g/mL), BMP-4 (1 ng/mL, Invitrogen
Life Technologies), and Rho kinase (ROCK) inhibitor
(10 𝜇M; R&D Systems, Minneapolis, MN, USA) under
hypoxic conditions for 24 h to form cardiogenic embryoid
bodies (cardiospheres). The culture was then washed and
incubated in StemPro34 SFM (Invitrogen Life Technologies)
containing ascorbic acid (50 𝜇g/mL; Sigma-Aldrich Co. LLC.,
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St. Louis, MO, USA), GlutaMAX-1 (2mM; Invitrogen Life
Technologies), BMP4 (10 ng/mL), and human recombinant
activin-A (10 ng/mL; Invitrogen Life Technologies) for 3 days.
On day 4, IWR-1 (4-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-
methano-2H-isoindol-2-yl)-N-8-quinolinyl-benzamide), a
small molecule Wnt inhibitor (5𝜇M/mL; Enzo Life Sciences
Inc., Farmingdale, NY, USA), was added to inhibit the
canonical Wnt signaling pathway. On day 8, the culture was
transferred to a normoxic environment and maintained in
StemPro34 SFM containing 50𝜇g/mL ascorbic acid alone.
At day 20 after the start of the cardiac differentiation pro-
cess, cardiospheres were dissociated with Ca2+ andMg2+-free
PBS containing collagenase IV (1mg/mL),DNase (10𝜇g/mL),
and 0.05% trypsin, after which they were transferred to
Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen
Life Technologies) containing 5% fetal calf serum (FCS),
2mM glutamine, 1% penicillin/streptomycin, and 100 𝜇M
nonessential amino acids (Invitrogen Life Technologies).The
cultures were maintained for 24 h at 37∘C in a humidified
environment with 5%CO
2
/95% air.The cells were then trans-
duced with the lentiviral construct LV-MLC2v-tdTomato-
T2A-Zeo as described previously [35] and ventricular car-
diomyocytes (hESC-vCMs) were specifically selected by
incubation with zeocin (300𝜇g/mL). The cells were allowed
to recover from the zeocin selection procedure in DMEM
containing normal 5% FCS for at least 96 h prior to the start
of the metabolic treatment experiments.
2.2. Treatment of hESC-vCMs with Metabolic Stimulants.
hESC-vCMs were plated onto glass cover slips (13mm in
diameter, No. 1.5H, Paul Marienfeld GmbH & Co. KG,
Lauda-Ko¨nigshofen, Germany) coated with poly-D-lysine
(5 𝜇g/cm3) and Matrigel at a density of 4 × 104 cells per
cover slip. After 24 h, the cells were treated with 0.3𝜇M
isoproterenol (Sigma-AldrichCo. LLC.) and/or either 100𝜇M
or 200𝜇Moleic acid (Sigma-AldrichCo. LLC.) for 96 h before
they were fixed with 4% paraformaldehyde in phosphate-
buffered solution (PBS; 137mM NaCl, 2.68mM KCl, 16mM
Na
2
HPO
4
, 5.2mM NaH
2
PO
4
, pH 7.3) for 15min. The fixed
cells were then washed thoroughly with PBS and then stored
in PBS at 4∘C prior to immunolabeling.
2.3. Immunolabeling. All the incubation steps used in this
protocol were performed in the dark at room temperature
(i.e., ∼22∘C). The isoproterenol and/or oleic acid-treated and
paraformaldehyde-fixed hESC-vCMs were incubated in PBS
containing 0.1% Triton X-100 (PBS-T) for 10min, after which
they were incubated in blocking buffer (PBS-T containing
10% goat serum and 1% bovine serum albumin; BSA) for
30min. The cells were then incubated sequentially with the
mouse monoclonal anti-sarcomeric 𝛼-actinin antibody (at a
dilution of 1 : 100; Abcam, Cambridge, UK) and the rabbit
polyclonal anti-COX IV antibody (at a dilution of 1 : 800;
Abcam). Both antibodies were diluted just prior to use with
blocking buffer. Alpha-actinin was then visualized using the
Alexa Fluor 488 F(ab󸀠)
2
fragment of the goat anti-mouse IgG
(H + L) antibody (at a dilution of 1 : 200; Invitrogen Life
Technologies). COX IV was visualized using an ATTO 647N
(STED/GSD) goat anti-rabbit IgG antibody (at a dilution
of 1 : 200; Active Motif, Carlsbad, CA, USA). Each antibody
incubation step lasted for 1 h; between each incubation the
hESC-vCMs were rinsed extensively with wash buffer (PBS-
T containing 1% goat serum and 0.1% BSA). Following a
final rinse with wash buffer, the cells were rinsed once
with Milli-Q water and then they were mounted under
ProLong Gold antifade reagent containing DAPI (Invitrogen
Life Technologies). The mounted cells were kept in the dark
overnight at room temperature and subsequently transferred
to 4∘C before visualization via confocal laser scanning and
multiphoton excitation microscopy.
2.4. Confocal Laser Scanning and Multiphoton Excita-
tion Microscopy. The fluorescence images of labeled car-
diomyocytes were acquired with a Leica TCS SP5 II
laser scanning confocal system mounted on a Leica DMI
6000 inverted microscope (Leica Microsystems, Wetzlar,
Germany) equipped with multiphoton excitation capacity.
Images were obtained using a Leica HCX PL APO 40x/1.25–
0.75 NA oil-immersion objective lens. Alexa Fluor 488
fluorescence was observed via confocal microscopy using
488 nm excitation and 500–550 nm emission, tdTomato fluo-
rescence was observed via confocal microscopy using 561 nm
excitation and 575–610 nm emission wavelengths, and ATTO
647N fluorescence was observed via confocal microscopy
using 633 nm excitation and 650–750 nm emission. DAPI
was visualized via multiphoton excitation microscopy using
780 nm excitation and 432–482 nm emission.
2.5. Data Analysis. Following immunolabeling and confocal
microscopy, the images of the cardiomyocytes generated
were analyzed using Image J (National Institutes of Health,
Bethesda, MD, USA). The shape of cardiomyocytes was
quantified using the “circularity” function. Images of cells
showing 𝛼-actinin labeling were used for this analysis. The
confocal microscope-generated scale bar included in each
imagewas used to calibrate the scale in Image J.Theperimeter
of the cell was then traced using the “Freehand Selections”
tool and the shape of the cell was subsequently determined,
such that a more rounded cell exhibited a circularity value
close to 1 whereas a more elongated cell had a value nearer to
0.Quantitative data analyseswere carried out usingMicrosoft
Office Excel 2010 (Microsoft, Redmond, WA, USA).
To quantify the orientation of themyofibrils in cardiomy-
ocytes, the “Multipoint” tool in Image J was used to analyze
the 𝛼-actinin labeled images. In each cell, a total of 32 𝑥, 𝑦
coordinates was applied to mark two points along the length
of each of 16 myofibrils. These coordinates were exported
to Excel and the slope (m) of the line connecting the two
points was calculated using the following equation:𝑚 = (𝑦
1
−
𝑦
2
)/(𝑥
1
−𝑥
2
).The variance (i.e., standard deviation2) of these
calculated slope values was then used to indicate if myofibrils
were running in parallel through a cell (in which case, they
would have a variance near to zero) or if they were distributed
in a randommanner (such that they would exhibit a relatively
higher variance value).
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To determine the level of intercalation between the 𝛼-
actinin-labeled myofibrils and the COX IV-labeled mito-
chondria, a line scan analysis was performed. The individual
confocal fluorescent images of 𝛼-actinin and COX IV were
opened in Image J and then stacked. The microscope-
generated scale bar was used to set the scale, and four straight
lines of between 20 𝜇m and 30 𝜇m in length and ∼1 𝜇m in
width were placed in areas of each cardiomyocyte where
the myofibrils were arranged in parallel such that the lines
were perpendicular to the orientation of the myofibrils. In
addition, lines were placed away from both the nucleus and
the outer edge of the cell. Two sets of numerical line scan
data were acquired for each line: one for the 𝛼-actinin image
and the other for the COX IV image. These data were then
exported to Excel for graph plotting and calculation of the
Pearson correlation coefficient.
Dunnett’s test was used to determine statistically signif-
icant differences between the data sets. This was performed
with the SPSS statistics software (IBM, Armonk, NY, USA).
3. Results
The effect of isoproterenol and oleic acid on hESC-vCM
maturation was determined by quantifying the cell shape,
cell area, orientation of the myofibrils, and the level of
intercalation of themitochondriawith themyofibrils. In these
experiments, a total of 309 cells was analyzed from 4 different
experiments.
3.1. Quantification of Cell Shape. hESC-vCMs were either
untreated or were treated with 0.3𝜇M isoproterenol; 100 𝜇M
or 200𝜇M oleic acid; or 0.3 𝜇M isoproterenol and either
100 𝜇M or 200𝜇M oleic acid. The cells were then immuno-
labeled with an 𝛼-actinin antibody to identify the myofib-
rils, after which the shape of the cells was quantified by
determining the circularity value such that a value of 1
indicates a perfect circle whereas a value of 0 indicates a
straight line (Figure 1(a) panel (A)). Representative examples
of cells treated with 0.3 𝜇M isoproterenol and 200𝜇M oleic
acid, which induces the greatest variation in shape of all the
treatments, are shown in Figures 1(a) panel (B)-1(a) panel (C).
These cells have circularity values of (Figure 1(a) panel (B))
∼0.31 Arb. Units (AU) and (Figure 1(a) panel (C)) ∼0.97AU,
respectively, with the cell in Figure 1(a) panel (B) showing
a relatively elongated morphology, while that in Figure 1(a)
panel (C) is more rounded.
A range of circularity values was observed whether the
hESC-vCMs were untreated or treated with isoproterenol
and/or oleic acid; these are shown in the series of histograms
in Figures 1(b)–1(g). Figure 1(b) shows the range of circularity
values obtained for the untreated control cells (𝑛 = 72),
such that ∼64.0% of cells exhibited circularity values of
between 0.8 and 1.0 Arb units (AU); ∼30.5% of cells exhibited
circularity values between 0.6 and 0.8AU, and ∼5.5% of
cells exhibited circularity values between 0.4 and 0.6AU.The
mean circularity was calculated to be 0.8 AU (see black arrow
in Figure 1(b)). When cells were treated with 0.3𝜇M isopro-
terenol (𝑛 = 49; Figure 1(c)), however, there was an overall
shift in the shape of cells from a more rounded to a more
elongated phenotype, when compared with the untreated
controls. This is reflected in a lower mean circularity value
of 0.73AU (see black arrow in Figure 1(c)). When treated
with 0.3𝜇M isoproterenol, ∼43.0% of the cells exhibited
circularity values of between 0.8 and 1.0 AU, ∼32.6% of cells
were between 0.6 and 0.8AU, ∼18.4% of cells were between
0.4 and 0.6AU, and ∼6.0% of cells exhibited circularity
values between 0.3 and 0.4AU (Figure 1(c)). Indeed, the
circularity values of cells treated with 0.3 𝜇M isoproterenol
were significantly lower than those of the untreated control
at 𝑝 ≤ 0.05 using Dunnett’s test. Figures 1(d) and 1(e)
show the spread of circularity values in cells treated with
100 𝜇M and 200 𝜇M oleic acid, respectively, and the black
arrows in these figures indicate mean values of 0.72AU and
0.70AU, respectively. When cells were treated with 100 𝜇M
oleic acid (𝑛 = 61; Figure 1(d)), the proportion exhibiting
circularity values between 0.8 and 1.0 AU, 0.6 and 0.8 AU,
0.4 and 0.6AU, and 0.2 and 0.4AU was ∼41.0%, ∼36.0%, ∼
16.4%, and ∼6.6% of cells, respectively. In addition, following
treatment with 200𝜇M oleic acid (𝑛 = 48; Figure 1(e)), the
proportion of cells exhibiting circularity values between 0.8
and 1.0 AU, 0.6 and 0.8 AU, 0.4 and 0.6AU, and 0.2 and
0.4AUwas∼35.4%,∼35.4%,∼25.0%, and∼4.2%, respectively.
Thus, the 100 𝜇M and 200𝜇M oleic acid treatments both
generated significantly more cells in the population with a
lower circularity value, than those in the untreated control
population at 𝑝 ≤ 0.01 using Dunnett’s test. Figures 1(f)
and 1(g) show the spread of circularity values in cells treated
with 0.3𝜇M isoproterenol and oleic acid at either 100𝜇M
(𝑛 = 31; Figure 1(f)) or 200𝜇M (𝑛 = 48; Figure 1(g)). With
0.3 𝜇M isoproterenol and 100 𝜇M oleic acid (Figure 1(f)), the
proportion of cells exhibiting circularity values between 0.8
and 1.0 AU, 0.6 and 0.8 AU, 0.4 and 0.6AU, and 0.2 and 0.4AU
was ∼22.6%, ∼22.6%, ∼25.8%, and ∼29.0%, respectively, and
a mean circularity value of 0.6 AU was calculated (see black
arrow in Figure 1(f)). With 0.3 𝜇M isoproterenol and 200𝜇M
oleic acid (Figure 1(g)), the proportion of cells exhibiting
circularity values between 0.8 and 1.0 AU, 0.6 and 0.8 AU,
0.4 and 0.6AU, and 0.2 and 0.4AU was ∼23.0%, ∼37.5%, ∼
18.7%, and ∼20.8%, respectively, and a mean circularity value
of 0.62AU was calculated (see black arrow in Figure 1(g)).
Thus, both of the 0.3 𝜇M isoproterenol/100𝜇Moleic acid and
0.3 𝜇Misoproterenol/200𝜇Moleic acid combined treatments
generated significantly more cells in the population with a
lower circularity value than those in the untreated control
population at 𝑝 ≤ 0.001.
3.2. Quantification of Cell Area. The effect of isoproterenol
and/or oleic acid treatment on cell area was also investigated
using the same populations of cells used for the cell shape
measurements. Similar to the circularity data, a range of
cell area values was obtained for each treatment as well as
for the untreated controls. The two representative untreated
hESC-vCMs shown in Figure 2 have areas of ∼2,170 𝜇m2
(Figure 2(a) panel (A)) and ∼10,025 𝜇m2 (Figure 2(a) panel
(B)).
The range of cell areas measured for each treatment
is shown in the series of histograms in Figures 2(b)–2(g).
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Figure 1: Effect of isoproterenol and oleic acid on the shape of hESC-vCMs. ((a) panel (A)) Schematic illustration to show that circularity
values of 0 and 1 represent a straight line and perfect circle, respectively. ((a) panel (B), (a) panel (C)) Representative examples of elongated
and rounded hESC-vCMs (labeled with an 𝛼-actinin antibody) that have circularity values of ((a) panel (B)) 0.31 AU and ((a) panel (C))
0.97AU, respectively. Scale bar is 30 𝜇m. (b–g) Histograms to show the distribution of cells (in %) exhibiting a particular circularity value in
(b) untreated controls and (c–g) following treatment with (c) 0.3 𝜇M isoproterenol, (d) 100𝜇M oleic acid, (e) 200 𝜇M oleic acid, (f) 0.3 𝜇M
isoproterenol plus 100 𝜇Moleic acid, or (g) 0.3 𝜇Misoproterenol plus 200 𝜇Moleic acid.The number of cells analyzed is indicated in the upper
left corner of each graph. The arrows indicate the mean circularity value determined for the population of cells, and the asterisks indicate
values that are significantly different from the untreated control at ∗𝑝 ≤ 0.05; ∗∗𝑝 ≤ 0.01; and ∗∗∗𝑝 ≤ 0.001.
Figure 2(b) shows the range of areas measured in the
untreated control cells, such that ∼5.5% of the cells exhibited
areas less than 4,000 𝜇m2, ∼50.0% exhibited areas between
4,000 𝜇m2 and 8,000 𝜇m2, ∼32.0% had areas between
8,000𝜇m2 and 12,000 𝜇m2, ∼11.1% had areas between
12,000 𝜇m2 and 16,000 𝜇m2, and ∼1.4% of cells exhibited
areas between 20,000𝜇m2 and 24,000𝜇m2. A mean cell area
of 8,109 𝜇m2 was calculated (see black arrow in Figure 2(b)).
Figures 2(c)–2(g) show the effects of the various treatments
on the cell area. In all cases, a similar range of areas was
calculated as for the untreated controls. For example, in all
cases, between 6% and 11% of cells had an area less than
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Figure 2: Effect of isoproterenol and oleic acid on the area of hESC-vCMs. ((a) panel (A), (a) panel (B)) Representative examples of the
typical areas of hESC-vCMs measured. These two cells (labeled with an 𝛼-actinin antibody) have cell areas of ((a) panel (A)) 2,170 𝜇m2 and
((a) panel (B)) 10,025 𝜇m2, respectively. Scale bar is 30 𝜇m. (b–g) Histograms to show the distribution of cells (in %) exhibiting a particular
cell area in (b) untreated controls and (c–g) following treatment with (c) 0.3𝜇M isoproterenol, (d) 100 𝜇M oleic acid, (e) 200 𝜇M oleic acid,
(f) 0.3 𝜇M isoproterenol plus 100 𝜇Moleic acid, or (g) 0.3 𝜇M isoproterenol plus 200 𝜇Moleic acid. The number of cells analyzed is indicated
in the upper left corner of each graph. In all treatment groups, none of the area values was significantly different from those of the untreated
controls. The arrows indicate the mean cell area determined for the population of cells.
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4,000 𝜇m2; the majority of cells (i.e., 62% to 83%, depending
on the treatment) had areas of 4,000 𝜇m2 and 12,000𝜇m2
such that 35% to 48% had areas between 4,000 𝜇m2 and
8,000𝜇m2 and 26% to 37.5% had areas between 8,000𝜇m2
and 12,000 𝜇m2
.
Of the remaining cells, 6.25% to 16% had
areas between 12,000 𝜇m2 and 16,000 𝜇m2, 3% to 8% had
areas between 16,000 𝜇m2 and 20,000𝜇m2, and 1.5% to 4%
of cells had areas between 20,000𝜇m2 and 28,000𝜇m2. In
addition, mean cell areas of 9,358 𝜇m2, 9,014 𝜇m2, 7,383 𝜇m2,
9,007𝜇m2, and 8,884 𝜇m2 were calculated for cells treated
with 0.3𝜇M isoproterenol, 100𝜇M oleic acid, 200𝜇M oleic
acid, 0.3𝜇M isoproterenol plus 100 𝜇Moleic acid, and 0.3 𝜇M
isoproterenol plus 200 𝜇M oleic acid, respectively (see black
arrowheads in Figures 2(c)–2(g)). None of the treatments
yielded area results that were significantly different from the
untreated controls using Dunnett’s test.
3.3. Quantifying the Orientation of the Myofibrils. The effect
of isoproterenol and/or oleic acid on the organization of
myofibrils was also investigated (Figure 3). Using the 𝛼-
actinin images used for the cell shape and areameasurements,
a series of short lines was drawn on top of and in the
same orientation as the myofibrils (i.e., perpendicular to the
sarcomeric 𝑧-lines) in each cell (Figures 3(a) panel (A)–3(a)
panel (C)). The value of the slope of each line was then
calculated, after which the variance of the slopes was deter-
mined. Cells with randomly oriented myofibrils exhibit a
relatively high variance value whereas those where myofibrils
are arranged in parallel have variance values approaching
zero. Figures 3(a) panel (A)–3(a) panel (C) show three
representative examples of untreated control hESC-vCMs to
illustrate the different patterns of myofibrillar organization;
these cells have slope variances of ∼0.02AU (Figure 3(a)
panel (A)), ∼124AU (Figure 3(a) panel (B)), and ∼486AU
(Figure 3(a) panel (C)).
The range of slope variances measured for each treatment
and the untreated controls is shown in the series of his-
tograms in Figures 3(b)–3(g).Whereas a relatively wide range
of variance values was observed for the untreated control
and each treatment group, we wanted to determine if any
of the treatments stimulated the formation of more parallel
myofibrils, when compared with the untreated control group.
Thus, we were most interested in the percentage of cells
with slope variance values between 0AU and 20AU. In the
untreated controls (𝑛 = 22), ∼46% cells had a variance value
of 0–20AU (Figure 3(b)). Similarly, when cells were treated
with isoproterenol alone (𝑛 = 19), ∼47% had a variance
value from 0 to 20AU (Figure 3(c)). When cells were treated
with 100 𝜇M oleic acid (𝑛 = 21; Figure 3(d)) or 200𝜇M oleic
acid (𝑛 = 23; Figure 3(e)), however, ∼67% and ∼70% cells,
respectively, had variance values between 0AU and 20AU.
Furthermore, when cells were treated with isoproterenol and
100 𝜇M oleic acid (𝑛 = 21; Figure 3(f)) or 200𝜇M oleic acid
(𝑛 = 23; Figure 3(g)), ∼81% and ∼70% cells, respectively, had
variance values between 0AU and 20AU. Thus, treatment
with oleic acid appeared to stimulate a larger number of cells
in the population to possess myofibrils that were oriented in
parallel.
3.4. Quantifying the Level of Intercalation of the Mitochon-
dria with the Myofibrils. Figure 4(a) shows a representative
example of an hESC-vCM that was immunolabeled with
antibodies to 𝛼-actinin and COX IV to label the myofibrils
and mitochondria, respectively. The cell was costained with
DAPI to label the nucleus. Line 1 indicates the location of one
of four line scan analyses that were conducted on this cell
to determine the level of intercalation of the mitochondria
with the myofibrils. In every cell that was tested for both the
treatments and the untreated controls, four lines were placed
away from the nucleus and perpendicular to the orientation
of the myofibrils. Figure 4(b) shows the two line graphs
produced from the line scan analysis performed along line
1 in Figure 4(a), such that the green and red lines show the
fluorescence intensity of 𝛼-actinin and COX IV, respectively.
The level of intercalation was then determined by calculating
the Pearson correlation coefficient (PCC), which in this case
equals ∼−0.03. The PCC ranges from +1 to −1, where +1
indicates a positive correlation and −1 indicates a negative
correlation or perfect exclusion, with zero indicating no
correlation (i.e., random distribution). Since the images have
a black background, the PCC will never be exactly +1 or −1;
however, a higher level of intercalation of mitochondria with
myofibrils is indicated by a more negative PCC value.
Figures 4(c)–4(h) are a series of scatter graphs showing
the PCC data from 80 line scans (4 line scans conducted per
cell in 20 cells) in the untreated controls and in each of the 5
different treatment groups. In the untreated (control) group,
37 line scans exhibited a positive PCC, whereas 43 line scans
had a negative PCC (Figure 4(c)). Similarly, in the 0.3𝜇M
isoproterenol group, there was an exact 1 : 1 split between
positive and negative PCC values such that 40 lines exhibited
positive PCC values and 40 had negative values (Figure 4(d)).
In the 100 𝜇M and 200𝜇M oleic acid treatment groups, the
PCC values obtained were almost identical such that 33 and
32 lines exhibited positive PCC values, respectively, and 47
and 48 lines exhibited negative values, respectively (Figures
4(e) and 4(f)). In addition, in the 0.3 𝜇M isoproterenol and
100 𝜇M oleic acid, and the 0.3 𝜇M isoproterenol and 200𝜇M
oleic acid groups, the number of line scans with positive and
negative PCC values was identical, such that, in both cases, 26
lines had positive PCC values whereas 54 lines had negative
values (Figures 4(g) and 4(h)).
4. Discussion
It has been previously reported by several groups that embry-
onic stem cells induced to differentiate into cardiac lineage
cells undergo a change in size and shape as they mature [5,
23, 36–38]. Differentiation is also accompanied by changes in
the ultrastructure, cell cycle, and metabolic properties of the
cell. In the developing mouse heart, for example, it has been
reported that early embryonic cardiomyocytes are polygonal
in shape and the myofibrils are oriented randomly through-
out the cytoplasm; however, during fetal development, these
cells become more elongated and the myofibrils become
progressively more aligned, ultimately developing a very
well organized cytoarchitecture [5]. More recently, Lundy
et al. [38] demonstrated that late-stage human ESC-CMs
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Figure 3: Effect of isoproterenol and oleic acid on the orientation of myofibrils in the hESC-vCMs. ((a) panel (A)–(a) panel (C)) The
orientation of the myofibrils localized within hESC-vCMs was determined by calculating the slope of lines placed along the length of the
myofibrils. ((a) panel (A)) hESC-vCMs with the myofibrils arranged in parallel exhibited a low slope variance (SV) value (e.g., 0.02AU),
when compared with ((a) panel (B)) cells where the myofibrils were arranged in a concentric manner and exhibit an SV of ∼124AU or ((a)
panel (C)) where the myofibrils were arranged in an irregular orientation when the SV was greater again (e.g., ∼480AU). Scale bar is 30 𝜇m.
(b–g) Histograms to show the distribution of cells (in %) exhibiting a particular variance value in (b) untreated controls and (c–g) following
treatment with (c) 0.3 𝜇M isoproterenol, (d) 100𝜇M oleic acid, (e) 200 𝜇M oleic acid, (f) 0.3 𝜇M isoproterenol plus 100 𝜇M oleic acid, or (g)
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Figure 4: Effect of isoproterenol and oleic acid on the intercalation of the mitochondria between the myofibrils. (a) Representative example
of an hESC-vCM that had been immunolabeled with antibodies to 𝛼-actinin and COX IV and costained with DAPI, to label the myofibrils,
mitochondria, and nucleus, respectively. Four line scan analyses were then performed per cell, such that the lines were placed perpendicular
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was calculated to be −0.03. (c–h) Series of scatter graphs to show the PCC determined for each of 4 lines in 𝑛 = 20 cells in (c) untreated
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and iPSC-CMs (i.e., at between 80 and 100 days of in vitro
differentiation and culturing) are larger in size and exhibit
a greater level of anisotropy, as well as a higher density of
myofibrils and amore organized pattern of sarcomeres, when
compared with early-stage cells of 20–40 days. In addition,
cardiomyocytes isolated from mature tissues and placed in
culture conditions undergo specific morphological changes
that are associated with dedifferentiation. For example, when
human adult atrial and ventricularmyocytes are isolated from
patients undergoing cardiac surgery, the cells are initially rod
shaped [39]. However, on dedifferentiation, the cells undergo
a loss of sarcomeric structure and concomitant change in
shape. When these cells are subsequently cultured in low
serum, they can then redifferentiate such that all the cells
flatten and spread and they either become large in size, with
nascent myofibrils, or smaller with a more mature pattern of
myofibrillar organization [39].
Before cells can be used for clinical purposes, their
phenotypic properties need to be characterized in detail.
Indeed, it has commonly been agreed that the morphological
and ultrastructural properties of cells must be investigated
as these are key characteristics that determine the differ-
entiation status of cells and hence their ability to perform
in cell replacement and transplantation procedures [36].
The importance of making precise observations and thus
acquiring detailed information regarding the changes that
occur during differentiation at the level of individual cells
has been emphasized previously [40]. Indeed, in recent years,
confocal laser scanning microscopy has become a popular
tool for exploring different aspects of cardiomyocyte differ-
entiation. These include studies of the migration of neural
crest-derived stem cells in the developing heart field and their
subsequent differentiation into cardiomyocytes [41], and
the successful transplantation of bone marrow-derived car-
diomyocytes expressing myosin light chain-2v-derived GFP
into the mouse heart [42]. Such observations have helped to
elucidate, at a cellular level, the mechanisms and pathways
that are involved in the formation of a functional heart during
development [5]. It is also crucial, however, to confirm single
cell observations that might be more qualitative in nature,
with quantitative information regarding the precise nature
of maturity of cells. Indeed, here we immunolabeled hESC-
vCMs, used confocal microscopy to acquire images of the
cells, and then developed quantitative methods to determine
their level of maturity. In these experiments, all the cells were
of a similar age (i.e., approximately 20 to 30 days; what Lundy
et al. [38] classed as an “early” stage of differentiation) and we
tested the effect of two metabolic agents (i.e., isoproterenol
and oleic acid) on the maturity of cardiomyocytes, when
compared with untreated (control) cells. As it would be
impractical to acquire high-magnification confocal images
from the large numbers of cells that are required for other
types of experiments, such as some biochemical assays, our
n-numbers are not large. In addition, it is clear that for all
the parameters we measured, a range of effects was observed
within the population and it is for this reason that we
presented the results in either histogram or scatter diagram
form. It was therefore important to show the data in this
way to emphasize the fact that the individual cells within
a population do show morphological variation and thus
simply presenting mean values does not necessarily give an
accurate measure of cellular phenotype.
Cell shape was the first parameter that we measured
to analyze the maturity of cardiomyocytes (Figure 1). A so-
called “shape factor” (what we call circularity value) has
previously been utilized when comparing the shape of H7-
and RuES-2-derived hESC-CMs during early (i.e., 20–40
days) and late (i.e., 80–120 days) differentiation [38]. The
shape factor has also been used to determine the level of
differentiation of hESCs but in this case it was the shape of
the nuclei that was quantified [43]. Our data showed that in
the untreated control group, the majority of cells had a more
rounded morphology, with around 70% of the population
exhibiting a circularity of 0.8 arbitrary units (AU) and above.
In all the treatment groups (i.e., the isoproterenol or oleic acid
alone groups, or the isoproterenol plus oleic acid groups),
a subset of cells also had a circular phenotype. However,
in each treatment group a higher proportion of cells had
a more elongated morphology, indicating a more mature
phenotype. Typically, adult ventricular cardiomyocytes from
human biopsies are rod-shaped [39] and so, using images
of such cells published previously [44, 45], we determined
the circularity value to be ∼0.5 AU. In our measurements,
however, the lowest circularity values we measured were
in the range of 0.2–0.3 AU and the cells exhibited a more
spindle-shaped morphology (Figure 1(a) panel (B)). As the
shape of cardiomyocytes is proposed to have a direct impact
on their contractility, via the way that the sarcomeres are
registered laterally [37], we suggest that the difference in
circularity values obtained for adult cardiomyocytes and the
maturing cardiomyocytes used in our study might reflect
the differences in maturity of these cells. When comparing
the various treatment groups, oleic acid alone had a more
profound effect on cell shape than isoproterenol but a com-
bination of the two together stimulated a higher proportion
of the cells to exhibit a more elongated morphology than
when either was used alone. Our data suggest that providing
a source of energy to the cells and promoting the maturation
of energy metabolism (via oleic acid [29, 31]) might be
more important at these early stages of maturation than
stimulating an influx of Ca2+ (via isoproterenol [25, 26])
but that when both are used together, their different actions
are complementary to help promote cell elongation and thus
maturation.
Although both isoproterenol and oleic acid clearly
affected the cell shape, neither of them (either when used
alone or together) appeared to have a significant effect on
the cell area (Figure 2). Similar to the cell shape data, a
range of different cell areas was observed for the controls
and in each treatment group such that the smallest and
largest cell areas were ∼2,000 𝜇m2 and ∼24,000–28,000𝜇m2,
respectively. However, the spread of area values was very
similar in all the groups, indicating that not one treatment
affected the cell area any more or less than the others.
Previously, Lundy et al. [38] reported that the size of H7-
and RuES-2-derived hESC-CMs increased from ∼480 𝜇m2 to
∼1,700 𝜇m2 from early (20–40 day) to late (20–40 day) stages,
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respectively, using similar methods to those we employed.
The size of the hESC-vCMs derived from hES2 cells that
we were using appeared to be at least 10–20-fold larger than
those described previously [38] (i.e., the majority of the
untreated control hES2-derived ventricular cardiomyocytes
were ∼4,000–8,000𝜇m2 when compared with just ∼480𝜇m2
of H7 and RuES-2-derived cardiomyocytes, at a comparable
stage of differentiation). Again using images published previ-
ously [44, 45], we determined that human adult ventricular
cardiomyocytes have a typical cell area of ∼4,300 𝜇m2, which
is somewhat similar to the area values that we obtained.
We suggest that the cell area differences observed between
our data and those previously reported might be due to
the different source of stem cells and/or the fact that the
concentration of cells plated out at the start of the experiment
varied [38].
It has been previously reported that the alignment of
myofibrils in immature cardiomyocytes is random and rela-
tively disorganized, whereasmature cardiomyocytes exhibit a
well-alignedmyofibrillar cytoarchitecture [24, 36, 38, 46–49].
These previous studies, however, did not quantify the level of
organization ofmyofibrils in the cells. In our data analysis, on
the other hand, we quantified the slope variance of myofibrils
in the untreated control cell group as well as in those treated
with isoproterenol or oleic acid alone, or with a combination
of the two (Figure 3). Cells with randomly orientedmyofibrils
were expected to exhibit a relatively high variance value
whereas those where the myofibrils were arranged in parallel
were expected to have variance values approaching zero.
We were thus most interested in determining the percent
of cells with the lowest variance values (i.e., between 0 and
20AU; see grey bar in Figure 3(b)). A similar method was
previously used to determine the alignment of human iPSC-
CMs on microgrooved and non-microgrooved scaffolds,
whereby the variance values of the angle of the long axis of
the nuclei relative to the horizontal axis of the image field
were measured and the smaller the value then the more well-
aligned the population of cells was determined to be [22]. In
our experiments, we found that the percent of isoproterenol-
treated cells that exhibited more parallel myofibrils was very
similar (i.e., ∼46%) to that of the untreated controls (i.e.,
∼47%), suggesting that this metabolic stimulant does not
have any significant effect on the development of myofibrillar
organization in these cells. On the other hand, when cells
were treated with oleic acid, either alone (at 100𝜇M or
200𝜇M) or in combination with isoproterenol, a higher
percentage of cells exhibit more parallel myofibrils (i.e., from
∼68% to ∼80%, depending on the treatment; Figures 3(d)–
3(g)). These results therefore indicate that oleic acid might
stimulate this key aspect of cardiomyocyte maturation.
Cardiogenesis, whether it occurs during embryogenesis
or during heart repair, is known to involve the differentiation
of noncontractile stem cells with few energy requirements,
into energetically proficient contracting cardiomyocytes [24].
This transition therefore requires the formation and matura-
tion of a competent mitochondrial network. It has previously
been shown that the organization of the mitochondrial
network changes as cardiomyocytes mature, such that in
less mature cells the mitochondria exhibit a variety of ran-
dom, perinuclear, and transcellular arrangements, whereas,
in more mature cardiomyocytes, the mitochondria become
intercalated in between the myofibrils, forming functional
energetic units that facilitate energy production and EC-
coupling during contraction [24]. As a consequence, it has
been suggested that the localization and structure (which
subsequently affect the function) of the mitochondria in
cardiomyocytes are good indicators of the stage of differ-
entiation or maturity of cells [50]. While the metabolic
mechanisms that drive cardiac development are still largely
unknown, it has been previously shown that a combination
of𝛽-adrenergic stimulation and fatty acid supplementation to
mimic the postnatal development process leads to increased
mitochondrial energetics [23]. Chung et al. [24] nicely
demonstrated the intercalation of the mitochondria with the
myofibrils using line scan analysis. We have now taken this
one step further and quantified the level of intercalation using
Pearson correlation coefficient, which is frequently used in
biometrics to provide a measure of colocalization of two flu-
orescent signals [51] but in this case was used to indicate the
amount of separation (or exclusion) of two signals.The scatter
graphs shown in Figure 4 illustrate the level of intercalation
along line scans from 4 distinct regions in each of 20 cells for
each of the untreated controls and the various isoproterenol
and oleic acid treatments. Our data clearly show that, even
within one cell, the level of localization of mitochondria and
myofibrils might vary considerably in different regions. This
is especially so in the untreated cells and in those treated with
isoproterenol alone (Figures 4(c) and 4(d)). When cells were
treated with oleic acid (at either 100𝜇Mor 200𝜇M), however,
a higher level of intercalation was observed, as shown by
the higher number of lines exhibiting a negative Pearson
correlation value than a positive value (Figures 4(e) and 4(f)).
Cells treated with a combination of isoproterenol and oleic
acid (again at either 100 𝜇M or 200𝜇M) showed an even
greater level ofmitochondria intercalationwith over twice the
number of line scans having a negative Pearson correlation
than positive (Figures 4(g) and 4(h)).
5. Conclusions
In conclusion, we used four different morphometricmethods
to quantify the level of maturation of hESC-vCMs that were
either untreated or else treated with themetabolic stimulants,
isoproterenol and oleic acid, either alone or in combination.
Using these quantification methods, we showed that these
metabolic stimulants had an effect on some aspects of a cell’s
morphology but not on others. For example, isoproterenol
had an effect on cell shape but did not seem to affect the
cell area, the organization of the myofibrils, and (therefore
perhaps somewhat unsurprisingly) the intercalation of mito-
chondria with the myofibrils. On the other hand, oleic acid
(at both concentrations used) had a clear effect on cell shape,
the orientation of the myofibrils, and the intercalation of the
mitochondria with the myofibrils. When isoproterenol and
oleic acid were used together, they had an obviously syner-
gistic effect on cell shape andmitochondrial intercalation but
perhaps less of an effect on the orientation of the myofibrils.
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None of these treatments, however, appeared to affect the cell
area.
We suggest that these quantitativemethodsmight provide
simple and effective tools by which morphological matura-
tion data can be compared both within one type of cell and
between different cell types. Because of the wide variation
in the data obtained for individual cells within the popu-
lation, it is particularly important to show the distribution
of the data in order to conduct accurate data analysis. In
this way, changes in the overall trend of the data can be
detected more clearly than if means and standard deviations
(or standard errors) are presented. We suggest that these
simple morphometric techniques might be adopted by other
researchers in the field to more accurately describe the state
of morphological maturation of ESC-CMs and iPSC-CMs in
addition to the qualitative data that are already presented.
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